Kaida BioPharma was founded on the research principles and clinical evidence of G129R, a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors.

Kaida is advancing targeted anti-cancer hormonal therapies to address the root cause of cancers affecting women. The Company’s lead program, KAD101 is a novel biologic that blocks the prolactin ...

“We are proud to partner with Kaida BioPharma on the development of KAD101,” added Vladas Algirdas Bumelis, PhD, CEO, and Chairman of Northway Biotech.

Kaida is advancing targeted anti-cancer hormonal therapies to address the root cause of cancers affecting women. The Company's lead program, KAD101 is a novel biologic that blocks the prolactin ...

Liu Chang An, Kaida CEO and chairman, said: “ Compared with the 10-30% peeling loss with mechanical peeling, Kaida’s new facility in Beijing has a 6% loss, which will generate an additional 1,150 – ...

WALTHAM, MASSACHUSETTS / ACCESS Newswire / May 21, 2025 / Northway Biotech, Inc. ("Northway Biotech"), an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), and Kaida ...

FORT LAUDERDALE, FL, May 21, 2025 (GLOBE NEWSWIRE) -- Kaida BioPharma ("Kaida” or the "Company”), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone ...

Leveraging Northway Biotech's 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for hormone-driven ovarian cancer WALTHAM, MASSACHUSETTS / ACCESS Newswire / May ...